Technology evaluation: HspE7, StressGen Biotechnologies Corp.

Article Details

Citation
Copy to clipboard

Hunt S

Technology evaluation: HspE7, StressGen Biotechnologies Corp.

Curr Opin Mol Ther. 2001 Aug;3(4):413-7.

PubMed ID
11525566 [ View in PubMed
]
Abstract

StressGen is developing HspE7 (SGN-00101) as a potential therapy for human papillomavirus (HPV)-associated conditions. It is a recombinant fusion protein comprising the HPV E7 antigen and the heat shock protein, hsp65, from Mycobacterium bovis. By November 2000, it was in phase III trials for HPV-related anal dysplasia [405228]. Under an aggrement formed in November 1999, the US National Cancer Institute (NCI) is carrying out clinical trials with StressGen in diseases caused by HPV [347155].

DrugBank Data that Cites this Article

Drugs